Oslo, Norway, March 24, 2026 - Lytix Biopharma AS ("Lytix") (Euronext Growth Oslo: LYTIX), a clinical-stage immuno-oncology company, has today published its Annual Report for 2025, which was approved by the board of directors on March 23, 2026. 

2025 marked a defining year for Lytix, with continued clinical progress, important strategic advancements, and a clearer pathway toward late-stage development and commercialization of its lead candidate, ruxotemitide (formerly LTX-315). 

"2025 has been a defining year for Lytix Biopharma," said Øystein Rekdal, CEO of Lytix Biopharma. "We have strengthened the clinical foundation of our technology platform through multiple Phase II studies, including encouraging interim results from the NeoLIPA study in neoadjuvant melanoma. At the same time, our partner Verrica has continued to advance the basal cell carcinoma program toward Phase III, supported by new immune-response data. Combined with a more focused strategy and strengthened organization, this positions Lytix for the next phase of development as we work toward commercialization and strategic partnerships." 

During the year, Lytix reported positive interim data from the NeoLIPA Phase II study, demonstrating a 44% pathological complete response rate and an overall pathological response of approximately 90% among the first evaluable patients. In parallel, the ATLAS-IT-05 study in advanced melanoma confirmed systemic immune activation and durable disease control in a heavily pretreated patient population. 

The company also continued to support its partner Verrica Pharmaceuticals in advancing ruxotemitide toward a potential Phase III program in basal cell carcinoma, while progressing preparations for clinical entry of its next-generation candidate, LTX-401. 

Following the reporting period, Lytix strengthened its financial position through a private placement and subsequent offering raising total gross proceeds of approximately NOK 77.3 million, providing financial flexibility to advance its development programs. 

The Annual Report for 2025 is attached to this notice and is also available on the company's website, www.lytixbiopharma.com, under Investors. 

For further information, please contact: 

Gjest Breistein, CFO 

E-mail: gjest.breistein@lytixbiopharma.com

Phone: +47 952 60 512 

About Lytix Biopharma 

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company developing novel immunotherapies based on oncolytic peptides that directly kill tumor cells and activate the immune system to target solid tumors. The company's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule being evaluated across multiple cancer indications and treatment settings, both as monotherapy and in combination with immune checkpoint inhibitors.